The results show that the TREX1 inhibitors developed by Sprint Bioscience within the DISA program led to the activation of immune signaling in cancer cells from different types of tumors and that they have an effect that surpasses other inhibitors that are under development by other companies. The results have increased the understanding of how the TREX1 protein acts in cancer cells and how it enables these cells to escape the immune system.
"The results increase the mechanistic understanding and provide further support that inhibition of TREX1 has the opportunity to develop into a treatment option for patients with various types of cancer. We are proud to be able to present these data to the foremost researchers in the field," says Martin Andersson, CSO at Sprint Bioscience.
STING & TLR-Targeting Therapies Summit is a specialized conference with participants from companies and academic groups that focus on research and drug development with the aim of blocking the ability of cancer cells to escape the immune response in the tumor. The conference covers everything from basic research to clinical trials and many present previously completely unpublished information.
The poster ‘Fragment-based drug development of TREX1 inhibitors’ is presented by Yasmin Yu, Ph.D., Senior Scientist, Sprint Bioscience.

For further information, kindly contact:
 
Martin Andersson, CSO, Sprint Bioscience
Tel: 08-411 44 55
Epost: martin.andersson@sprintbioscience.com